AlphaLiquid® Detect is an industry-first tumor-informed, hybrid-capture NGS-based liquid biopsy test designed for MRD detection and recurrence monitoring in stage I-III solid tumor patients. The assay incorporates a personalized panel of up to 1,000 targets, including both tumor-informed patient-specific markers as well as additional therapeutic targets.
By delivering exceptional detection levels (<0.005% LOD), AlphaLiquid® Detect provides clinically actionable information for relapse monitoring and adjuvant therapy guidance with a significant lead time over conventional imaging diagnostics.
Assay Type | Tumor tissue sequencing Targeted hybrid capture NGS based on proprietary HQS™ technology |
---|---|
Sample Requirement | Tissue : FFPE (10μm x 10 sections) or FF Blood : >20mL of whole blood |
Targets | Customized panel of up to 1,000 targets |
Detected Alterations | SNVs and Indels |
Limit of Detection | 0.005% ~ 0.0005% ctDNA fraction |